✦ LIBER ✦

A novel, selective and orally-available glucosylceramide synthase inhibitor for substrate reduction therapy of Fabry disease

✍ Scribed by Ashe, Karen; Marshall, John; Budman, Eva; Bangari, Dinesh; Nietupski, Jennifer; Desnick, Robert; Scheule, Ronald; Leonard, John; Cheng, Seng

Book ID: 122364650
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 58 KB
Volume: 108
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2012.11.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

24 Genz-112638: A novel orally available

24 Genz-112638: A novel orally available ceramide-based inhibitor of glucosylceramide synthase for treating Gaucher disease

✍ Kerry McEachern; C. Siegel; J. Fung; W.L. Chuang; E. Hutto; C. Sung; L. Blankste 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Preclinical characterization of RO460252

Preclinical characterization of RO4602522, a novel, selective and orally active monoamine oxidase type B inhibitor for the treatment of Alzheimer's disease

✍ Borroni, Edilio; Wyler, Rene; Messer, Juergen; Nave, Stephane; Cesura, Andrea 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Selective inhibition of spleen tyrosine

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

✍ Liao, Cheng; Hsu, Jonathan; Kim, Yong; Hu, Dong-Qing; Xu, Daigen; Zhang, Jun; Pa 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 893 KB